A new microbiome company Lodo Therapeutics Corp. and a T-cell receptor (TCR) focused firm Tmunity Therapeutics Inc. were among the new companies and VC funding rounds in early-stage biotechs announced during the second week of 2016.
The announcements may have helped lighten conversations at the J P Morgan meeting in San Francisco, improving sentiment otherwise weighed...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
